Common Side Effects of Edoxaban
Bleeding is the most common and clinically significant adverse effect of edoxaban, with gastrointestinal bleeding being particularly notable. 1
Primary Adverse Effects
Bleeding Complications
Major bleeding occurs in approximately 3.09% of patients per year on edoxaban compared to 3.45% with warfarin 1. The bleeding profile includes:
- Gastrointestinal bleeding: Edoxaban shows comparable rates to warfarin (0.86% vs 1.24% per year), which is notably lower than dabigatran's increased GI bleeding risk 1
- Intracranial bleeding: Significantly reduced compared to warfarin (0.80% vs 0.74% per year) 1
- Hemorrhagic stroke: Substantially lower than warfarin (0.47% vs 0.44% per year) 1
Gastrointestinal-Specific Risks
Patients with gastrointestinal cancers face significantly elevated bleeding risk with edoxaban. In the Hokusai-VTE Cancer trial, patients with GI malignancies had higher major bleeding rates (6.9% vs 4.0% with dalteparin), with upper GI bleeding comprising 71.4% of major bleeding events in the edoxaban group 2. This represents a critical clinical consideration requiring heightened vigilance.
Recent case reports have identified edoxaban-induced enterocolitis as a rare but distinct adverse effect, presenting with bloody diarrhea, scattered ulcers, erosions, and submucosal bleeding throughout the colon 3. While uncommon, this may be underrecognized in clinical practice.
Less Common but Serious Adverse Effects
Hepatobiliary Complications
- Elevated liver enzymes: Serum bilirubin and gamma-glutamyl transpeptidase elevation are described as common events 4
- Vanishing bile duct syndrome: One fatal case has been reported, though this remains extremely rare 4
Renal and Urinary System
Edoxaban demonstrates a more prominent risk profile for kidney and urinary system adverse events compared to other factor Xa inhibitors 5. This is particularly relevant given that 50% of edoxaban is renally cleared 6, 7.
Dosing-Related Considerations
Underdosing Risk
Low edoxaban concentrations are significantly associated with thromboembolic events (adjusted HR 4.13 [1.08-15.82]) 8. The 15 mg dose in elderly patients with creatinine clearance >50 mL/min results in >50% probability of subtherapeutic drug levels, potentially increasing stroke risk 8.
High Creatinine Clearance
The FDA has issued a warning about reduced efficacy in patients with creatinine clearance >95 mL/min, recommending alternative anticoagulants in this population 7. This represents a unique limitation not seen with other DOACs.
Comparative Safety Profile
In disproportionality analysis of the FDA Adverse Event Reporting System:
- Rivaroxaban carries the highest hemorrhage risk among factor Xa inhibitors
- Apixaban shows higher incidence of death and cardiac/cerebral adverse events
- Edoxaban demonstrates the most prominent kidney/urinary system risks 5
Clinical Monitoring Implications
Renal function requires diligent monitoring (at minimum yearly, more frequently if CrCl <60 mL/min) 7. The half-life of edoxaban is 10-14 hours, with bioavailability of 62% 7. Unlike some other DOACs, food intake has minimal effect on absorption (6-22% increase, not clinically significant) 7.
No reversal agent is currently FDA-approved for edoxaban, though andexanet alfa and ciraparantag are under investigation 9.